Login / Signup

Active surveillance in intermediate-risk prostate cancer with PSA 10-20 ng/mL: pathological outcome analysis of a population-level database.

Peter E LonerganChang Wook JeongSamuel L WashingtonAnnika HerlemannScarlett Lin GomezPeter R CarrollMatthew R Cooperberg
Published in: Prostate cancer and prostatic diseases (2021)
Our results support extending AS criteria more permissively to carefully selected men with PSA 10-20 ng/mL and GG 1 disease.
Keyphrases
  • prostate cancer
  • radical prostatectomy
  • middle aged
  • adverse drug
  • emergency department
  • drug induced